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ABSTRACT
Background/aim: Little is known about biochemical
markers related to change in visual acuity after
vitrectomy. The potential use of transthyretin (TTR), a
carrier of the retinol/retinol-binding protein, as a
biochemical marker protein, was investigated.
Methods: TTR was measured using immunonephelome-
try in a group of patients (n = 77) in longstanding
(.1 week) retinal detachment (n = 29), fresh (,1 week)
retinal detachment (n = 17), macular holes (n = 20) or
diabetic retinopathy (n = 11). Vitreous samples were taken
at the start of every vitrectomy procedure. For reference
values, cadaver specimens (n = 73) were used.
Results: Reference values for vitreous TTR (median
18 mg/l; IQR 4 to 24 mg/l) comprised 2.2% of reference
values for vitreous protein levels (median 538 mg/l; IQR
269 to 987 mg/l). Vitreous TTR values of patients were
comparable in all disorders. Vitreous TTR values were
higher in phakic (median 22.5 mg/l; IQR 10 to 27 mg/l)
than in pseudophakic patients (median 12 mg/l; IQR 8 to
19 mg/l; p = 0.06). Postoperative change in visual acuity
correlated well with vitreous TTR values found peropera-
tively (rs = 0.408; p = 0.012). Both change in visual
acuity and lens status were the only variables which
proved to explain the variance of TTR (multiple correlation
coefficient: 0.494; phakic status: t = 2.767; p = 0.0084;
and change in visual acuity t = 2.924: p = 0.0056).
Conclusion: Vitreous fluid concentrations of TTR can be
regarded as a biochemical marker for retinal function.
Transthyretin (TTR) is a 55 kDa homotetrameric
protein with a dimer configuration that is synthe-
sised in the liver, choroid plexus, visceral yolk sac
and retinal pigment epithelium. Each monomer is a
127-residue polypeptide rich in beta sheet struc-
ture. Association of two monomers forms an
extended beta sandwich. Further association of
another identical set of monomers produces the
homotetrameric structure. In serum, it functions as
a carrier for thyroxin and retinol-binding protein
(RBP). It has two thyroxin-binding sites per
tetramer at the interface between the latter set of
dimers, and two binding sites for RBP on the outer
surface. As a carrier protein for thyroxin in serum,
it acts in concert with thyroxin-binding globulin
and albumin. Retinol is transported bound to RBP,
which itself is bound to TTR.1 RBP has a higher
affinity for TTR when it is bound to a retinol
ester.2 The transport of protein-bound ligands
across lipid–water interfaces, such as cell mem-
brane surfaces, is thought to involve obligatory
dissociation of protein-bound ligand into the free
state before transmembrane transport.3 The reti-
nol–RBP–TTR complex cannot pass freely through
cell membranes. STRA6 is a multitransmembrane
domain protein functioning as the high-affinity
tissue receptor for plasma RBP and mediating
cellular uptake of vitamin A from the vitamin A-
RBP complex.4 It has been suggested that forma-
tion of the complex between TTR and single, or
multiple, RBP molecules prevents renal clearance of
the retinol/RBP complex.5
In the eye, TTR is bound to retinol and RBP in
various ocular tissues. In contrast to retinol, which
is derived solely from the serum, TTR is synthe-
sised locally. Plasma TTR does not cross the Bruch
membrane into the retina. Ocular TTR is synthe-
sised in the retinal pigment epithelium (RPE) and
in the pigmented epithelium of the ciliary body,
the corneal endothelium and the optic nerve fibre
layer of the retina, and is transported to specific
locations within the eye.6–8 Although the physio-
logical role of TTR in the eye is unknown, it is
possible that it participates in retinol cycling.
TTR can be deposited as amyloid fibrils in senile
systemic amyloidosis (SSA) and familial amyloid
polyneuropathy (FAP). At least 20 TTR mutations
are associated with amyloidosis.9 Vitreous amyloid
fibrils are the result of local synthesis of mutated
TTR. Nuclear cataract is associated with low
protein intake and low serum levels of TTR.10
Immunohistochemical analysis of drusen in
patients with age-related macular degeneration
showed the presence of TTR.11 Comparison of
aqueous humour between myopic and non-myopic
patients showed a higher TTR level in the former.12
There exist no biochemical markers to differ-
entiate between patients with excellent and poorer
visual acuity after vitrectomy. Little is known
about the TTR concentrations in normal and
pathological human vitreous fluid. As there are
no known reports of humans lacking TTR, the
importance of TTR to vision has not been
described. In view of the presumed key role of
TTR in the vitamin A cycle, we wanted to explore
the use of TTR in human vitreous fluid as a
biochemical marker protein for retinal function.
MATERIALS AND METHODS
Subjects
Vitreous samples obtained from human cadavers
(n = 73), obtained through a vitreous tap 4 mm
from the limbus in the temporal upper or lower
quadrant, were used for establishing references
values for TTR. In table 1, the age, sex, post-
mortem interval and possible pre-existing diseases
are provided. The median postmortem interval was
1.5 days (IQR 0.9 to 2.4 days). In addition, the
cause, mechanism and manner of death of each
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Table 1 Overview of the postmortem reference group: control cases; n = 73; age (years)
Case no
Age
(years) Sex
Postmortem
interval
(days) Cause of death Mechanism of death Manner of death Important pre-existing disease(s)
1 62 Female ¡2.50 Gunshot cal 9 mm Internal bleeding, HV shock Criminal Coronary bypass, generalised ATH, diabetes not excluded
2 82 Female ¡1.00 Parathion
intoxication
Letal ACH inhibition Suicide Depression
3 47 Male ¡1.00 Gastrointestinal
bleeding
Internal bleeding, HV shock Natural Alcohol abuse
4 21 Male 3.13 Drowning Mechanical asphyxia Accidental None
5 39 Male ¡1.5 Gunshot pistol cal
7.65
Craniocerebral trauma Criminal Liver steatosis
6 40 Male 3.13 Fall from stairs Subdural bleeding Accidental Slight CH (muscular)
7 31 Male 2.65 MDMA intoxication CP failure Accidental Chronic pyelonephritis
8 14 Female 3.52 Diving trauma Drowning Accidental None
9 38 Male 2.49 Stab wound Internal bleeding, HV shock Criminal None
10 26 Female ¡7 to 8 Intoxication Hypoxic encephalopathy; Accidental Cachexia; survival following intoxication (¡1 month)
pulmonary infection
11 60 Male 1.42 Multiple blunt
trauma
Craniocerebral trauma Criminal Alcohol abuse; liver steatosis; ATH aorta (third degree)
12 68 Female 1.80 Traffic accident Polytrauma Accidental ATH aorta (third degree)
13 58 Female 4.51 Polydrug
intoxication
CP failure Accidental CH (muscular); pulmonary HT; generalised ATH
14 42 Female 0.83 Shotgun cal 12 Internal bleeding, HV shock Criminal None
15 53 Male 1.83 Shotgun cal 12 Internal bleeding, HV shock Criminal ATH aorta abdominalis (third degree); pulmonary HT
16 33 Female 2.01 Strangulation Mechanical asphyxia Criminal None
17 83 Female 0.83 Multiple blunt
trauma
CP failure; HV shock Criminal? ATH aorta (third degree); non-recent pyelonephritis
18 55 Male 1.40 Multiple blunt
trauma on head
Cerebral death Criminal CH (muscular); ATH aorta (third degree)
19 56 Male 0.88 High GI bleeding Internal bleeding, HV shock Natural Alcohol abuse
20 73 Male 1.77 Entrapment in lift
shaft
Craniocerebral trauma Accidental Liver steatosis; generalised ATH (eg, 2-branch coronary)
benign nephrosclerosis
21 45 Female 1.39 Strangulation Mechanical asphyxia Criminal Liver steatosis; chronic thyroiditis
22 42 Female 1.83 Fall from height Polytrauma, HV shock Suicide Psychiatric patient
23 54 Male ¡1.50 Disordered DM type
I
Diabetic ketoacidosis Natural DM type I
24 65 Male 3.56 Traffic accident Craniocerebral trauma Accidental CH (three-branch coronary sclerosis; ischaemic
cardiomyopathy) liver steatosis; generalised ATH
25 80 Male 1.25 Hammer blows on
head and stab
wounds to neck
Craniocerebral trauma; HV
shock
Criminal DM type II, CH (1-branch coronary sclerosis); benign
nephroangiosclerosis; generalised ATH (aorta, cerebral
vessels)
26 59 Male 0.25 Undetermined Cardiopulmonary failure Natural Unspecified cardiac complaints
27 42 Female 1.15 Multiple stab
wounds (knife)
External and internal bleeding;
HV shock
Criminal Chronic pulmonary emphysema and pulmonary HT
Cardiac tamponnade
28 52 Male 0.83 Polydrug
intoxication
CP failure Accidental Alcohol and drug abuse
29 34 Male 0.85 Multiple stab
wounds (knife)
Internal bleeding; HV shock Criminal Alcohol abuse; liver steatosis; non-recent cerebral
contusions
30 39 Female 1.27 Multiple stab
wounds (knife) and
fall from height
Polytrauma and cardiac
tamponnade
Criminal Drepanocytosis; subacute pyelonephritis
31 21 Male 2.04 Polydrug
intoxication
CP failure Accidental? Chronic intravenous drug abuse (cf, foreign-body
granulomata lungs; hypertrophy LN); CH (muscular)
32 66 Male 1.50 Gastrointestinal
bleeding
HV shock Natural DM type II; alcohol abuse; arterial HT
33 58 Male 0.84 Shotgun cal 20 Brain stem laceration Criminal Liver steatosis; CH (muscular); ATH; pulmonary HT
34 35 Male 0.66 Polydrug
intoxication
CP failure Accidental Alcohol and drug abuse
35 39 Male 3.27 Cardiac pathology CP failure Natural CH (three-branch coronary sclerosis; ischaemic
cardiomyopathy)
36 62 Female 1.00 Fall from stairs and
hypothermia
Craniocerebral trauma Accidental None
37 53 Female 1.66 Fall from height Polytrauma Suicide Pulmonary HT; non-specific chronic hepatitis
(medication-related?); depression
38 49 Male ¡3.00 Hypothermia HV shock Accidental Alcohol abuse
39 29 Male 0.50 Hanging Mechanical asphyxia Suicide None
Continued
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Table 1 Continued
Case no
Age
(years) Sex
Postmortem
interval
(days) Cause of death Mechanism of death Manner of death Important pre-existing disease(s)
40 53 Male 0.42 Polydrug
intoxication
CP failure Accidental DM type II; alcohol abuse; arterial HT
41 84 Female ¡0.56 Cachexia: extreme
negligence
Bronchiolitis, Hypoglycaemia,
dehydration
Undetermined Chronic peptic oesophagitis; chronic pyelonephritis;
generalised ATH
42 46 Male ¡2.00 Alcohol intoxication
and fall
HV shock Undetermined Chronic pulmonary emphysema and HT; alcohol abuse
(liver steatosis and pancreas fibrosis); ATH aorta
43 20 Female 1.66 Manual
strangulation and
blunt trauma
Mechanical asphyxia Criminal None
44 19 Male ¡2.70 Disorderd DM type I Diabetic ketoacidosis Natural DM type I
45 43 Male ¡3.50 Polydrug
intoxication
CP failure Accidental CH (muscular); liver steatosis
46 47 Female 1.29 Cardiac pathology CP failure (cf, anteroseptal
infarction)
Natural CH (three-branch coronary sclerosis); angor pectoris
47 25 Female 3.83 Arthroscopy Multiple lung embolism Accidental None
48 37 Female 1.27 Hammerblows on
head
Craniocerebral trauma Criminal None
49 66 Male 0.50 Hanging over iron
wire
Mechanical asphyxia
(positional)
Accidental Epilepsy; alcohol abuse
50 28 Male ¡0.20 DM type I:
hypoglycaemia
CP failure Natural DM type I
51 38 Male 1.29 Thoracal stab
wound
HV shock Suicide CH (one-branch coronary sclerosis); liver steatosis
52 62 Male 2.74 Fall from height Polytrauma; HV shock Accidental Alcohol abuse; liver steatosis; psychiatric problems
53 35 Female ¡2.35 Stab wounds knife
and manual
strangulation
Mechanical asphyxia and HV
shock
Criminal Slight CH; non-specific portitis; localised pancreatitis;
chronic intravenous drug abuse
54 26 Male ¡0.50 Gunshot pistol cal
.45
Craniocerebral trauma Suicide Depression
55 51 Male ¡0.50 Ethanol intoxication (Sub)acute CP failure Accidental DM type I; chronic alcohol abuse; NB: no hypoglycaemia
at the time of death
56 92 Female ¡2.73 Sudden cardiac
death
(Sub)acute CP failure Natural Non-recent nefrectomy right and stenting right carotid
artery; arterial HT; benign nephrosclerosis left kidney
57 46 Female ¡1.25 Hanging Mechanical asphyxia Suicide Slight pulmonary HT; liver steatosis; depression
58 8 Male ¡1.66 Strangulation Mechanical asphyxia Murder Slight CH (muscular)
59 44 Male ¡0.75 Fall from stairs Cranio-cerebral trauma Accidental Alcohol and drug abuse
60 27 Male 7.79 Hanging MOF; hypoxic
encephalopathy
Suicide CH (muscular); chronic active hepatitis C
61 24 Male ¡0.50 Polydrug
intoxication
CP failure Suicide Depression
62 26 Female ¡1.00 CO intoxication and
disordered DM type
I
CP failure (CO and
ketoacidosis)
Accidental DM type I (including diabetic feet); spina bifida
63 46 Male ¡3.00 Multiple blunt
trauma
Craniocerebral trauma Criminal CH (muscular); liver steatosis; old trauma capitis and non-
recent subdural haematoma
64 77 Male ¡2.50 Hypothermia CP failure Accidental Cachexia; ATH (LAD, cerebral vessels)
benign nephrosclerosis; pulmonary HT
65 11 Female 0.94 Anaphylactic shock
(during
anaesthesia)
HV shock Natural Strabismus
66 51 Male 1.25 Stab wounds
abdomen
Internal bleeding; HV shock Criminal Alcohol abuse; generalised ATH; CH (three-branch
coronary atherosclerosis)
67 46 Male ¡0.50 Polydrug
intoxication
(Sub)acute CP failure Suicide Alcohol abuse; psychiatric patient
68 61 Male ¡0.20 Undetermined CP failure Natural DM type II, chronic obstructive pulmonary disease, arterial
HT; alcohol abuse
69 36 Male ¡1.66 Undetermined CP failure Natural DM type I
70 59 Male ¡1.25 Gastrointestinal
bleeding
CP failure and HV shock Natural Chronic non-steroid anti-inflammatory drug use for lower-
back pain; arterial HT
71 33 Male 4.27 Intoxication
(cocaine, ethanol)
CP failure due to VF Accidental CH (muscular and two-branch atherosclerotic coronary
disease)
72 46 Male 0.25 Undetermined CP failure Natural Hypercholesterolaemia
73 71 Female ¡1.00 Positional asphyxia Mechanical asphyxia Accidental Chronic venous ulcers both legs
ACH, acetylcholinesterase; ATH, atherosclerosis; cal, calibre; DM, diabetes mellitus; CH, cardiac hypertrophy; CP, cardiopulmonary failure; HT, hypertension; HV, hypovolaemic
shock.
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individual are specified. Furthermore, we analysed 77 freshly
collected vitreous fluid samples submitted to our laboratory.
Samples were collected by two vitreoretinal surgeons (MV in
the Rotterdam Eye Hospital, The Netherlands, and EVA in
Ghent University Hospital, Belgium). A vitreous tap of 0.5 ml
was performed at the start of every vitrectomy procedure via a
syringe connected to the collecting cannula of the vitreous
cutter. All samples were immediately stored at 4uC. Informed
consent was obtained from each patient. According to
diagnosis, the patient could be divided in longstanding retinal
detachment (n = 29), fresh retinal detachment (n = 17), macular
holes (n = 20) or advanced proliferative diabetic retinopathy
(n = 11). As definitions, we used: ‘‘longstanding retinal detach-
ment’’ for retinal detachments of patients with typical
symptoms for a retinal detachment for at least 1 week before
surgical intervention, ‘‘fresh retinal detachment’’ for retinal
detachments of patients with typical symptoms for a retinal
detachment for less than 1 week before surgical intervention,
‘‘macular hole’’ for stage 3 (.400 mm) macular holes charac-
terised by OCT existing more than 6 months and ‘‘advanced
proliferative diabetic retinopathy’’ for patients with a fundus
partially obscured by vitreous haemorrhage according to ETDRS
standards.13 Pre- and postoperative visual acuity are measured
using Snellen charts at 6 m.
Biochemical investigations
TTR was measured immunonephelometrically on undiluted
vitreous fluid samples using commercially available Behring
antibodies on a Behring Nephelometer II analyser (Dade
Behring) standardised against the widely accepted WHO/
College of American Pathologists Certified Reference Material
470. Total protein in vitreous fluid was measured by the
Pyrogallol Red method (n = 129) with Standard Reference
Material 917a as a standard and commercially available reagents
(Instruchemie, Delfzijl, The Netherlands) on a Modular P
system (Roche).14 The 2.5 and 97.5 percentiles of the human
cadaver specimens were used for calculating the reference
interval. All samples were kept frozen at 220uC until analysis.
The between-run coefficient of variation was 5.86%, and the
detection limit was 3.35 mg/l.
Clinical investigations
In the patient group, best-corrected visual acuity (Snellen) was
evaluated before and 3–4 months after vitrectomy. The
diagnosis of all preoperative conditions was made by fundu-
scopy by a trained vitreoretinal surgeon. Additionally, optical
coherence tomography (OCT) was performed for patients
presenting with a macular hole. Patients who had undergone
cataract surgery before were defined as ‘‘pseudophakic.’’
Patients who had not yet undergone cataract surgery or had
cataract surgery simultaneously with the vitrectomy were
defined as ‘‘phakic.’’ Characteristics of patients are found in
table 2.
Statistics
All p values ,0.05 were considered significant. Agreement
between data was evaluated using the Spearman rank analysis.
The lower limit of detection was calculated as the mean value
23 SD for a blank sample. Diagnostic accuracy was assessed by
ROC analysis using commercially available statistical software
Table 2 Characteristics of patients
Retinal detachment
.1 week
Retinal detachment
,1 week
Advanced proliferative
diabetic retinopathy Macular hole stage 3
No 29 17 11 20
Age (range) 71 (61 to 79) 57 (51 to 69) 56 (50 to 59) 71 (61 to 74)
Phakic 15 (52%) 6 (35%) 6 (55%) 14 (70%)
Men 13 (45%) 8 (47%) 7 (64%) 7 (35%)
Figure 1 Box–whisker plots for transthyretin (TTR) values in vitreous
samples of patients. Comparison between TTR values of pseudophakic
and phakic patients. p = 0.064; Mann–Whitney U test.
Figure 2 Correlation between vitreous transthyretin (TTR)
concentration in patients and change in visual acuity (VA)
postoperatively. Agreement was fair between the TTR concentration (x)
and the sight measurements (y). The following regression equation was
obtained: y (Snellen) = 0.0462+0.0042logX (mg/l); Spearman rho =
0.408; p = 0.012; 95% confidence interval 0.106 to 0.641.
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(MedCalc, SPSS, Chicago). The variance of TTR was studied
using a stepwise backward elimination logistic regression model,
starting with all covariates in the model followed by a stepwise
removal of the term associated with the highest p value.
RESULTS
Reference values
In the reference group (n = 73, median age: 46 years; IQR 35 to
58 years), the median total protein concentration was 538 mg/l
(IQR 269 to 987 mg/l). Considering the causes of death and the
pre-existing pathologies, our control cases were a varied group and
thus represent the normal population, including a few diabetics
(n = 10; see table 1). The distribution of total protein was skewed.
The median TTR concentration was 18 mg/l (IQR 4 to 24 mg/l)
(table 2). The concentration of TTR was correlated with the total
protein concentration of the vitreous fluid (correlation coefficient:
0.459; p,0.01). TTR concentrations were not significantly
affected by the postmortem interval.
Values in various pathological conditions
The preoperative and postoperative visual acuities are list in
table 3. The total protein levels in patients with fresh or
longstanding retinal detachment and in patients with prolifera-
tive diabetic retinopathy were higher than total protein reference
levels. Among the patient groups, the highest TTR values were
recorded in the patients presenting with proliferative diabetic
retinopathy and lowest in patients presenting with macular hole
stage 3 (table 4). The median TTR values in any pathological
condition did not differ statistically with reference TTR values.
TTR values in patients who were phakic prior to the vitrectomy
procedure (median 22.5 mg/l) were higher than in pseudophakic
patients (median 12 mg/l) (fig 1). TTR/total protein ratios were
calculated, as this ratio corrects for the vascular permeability
changes. TTR/total protein ratios in any disease did not differ
with reference TTR/total protein values. Preoperative vitreous
TTR values correlated well with the visual outcome following
treatment (fig 2). In a logistic regression model, both change in
Table 3 Preoperative visual acuity (VA), postoperative VA and change
in VA for all patients individually in Snellen (6 m)
VA
preoperatively
VA
postoperatively Change in VA
Retinal detachment 0.1 0.9 0.8
.1 week (n = 29) 0.7 1.0 0.3
0.2 0.7 0.5
0.003 0.017 0.014
0.16 0.3 0.14
0.1 0.1 0
0.05 0.9 0.85
0.05 0.7 0.65
0.003 0.4 0.397
0.02 0.6 0.58
0.003 0.02 0.017
0.003 0.2 0.197
0.7 0.7 0
0.003 0.2 0.197
0.1 0.16 0.06
1.0 0.7 20.3
0.05 0.2 0.15
0.003 0.017 0.004
0.017 0.3 0.283
0.9 0.8 20.1
0.1 0.16 0.06
0.4 0.4 0
0.2 0.16 20.04
0.02 0.02 0
0.003 0.2 0.197
0.003 0.15 0.147
0.003 0.6 0.597
0.017 0.16 0.143
0.2 0.16 20.04
Mean (SD) 0.2 (0.28) 0.4 (0.3) 0.2 (0.3)
Retinal detachment 0.003 0.4 0.397
,1 week (n = 17) 0.8 1 0.2
1.0 0.7 20.3
0.003 0.6 0.597
0.003 0.9 0.897
0.017 0.9 0.883
0.003 0.5 0.497
1.0 0.8 20.2
0.003 0.5 0.497
0.7 0.6 20.1
0.8 0.8 0
0.017 0.3 0.283
0.6 0.6 0
0.003 0.5 0.497
0.003 0.5 0.497
0.3 0.3 0
0.003 0.2 0.197
Mean (SD) 0.3 (0.4) 0.6 (0.2) 0.3 (0.3)
Advanced proliferative 0.1 0.3 0.2
diabetic retinopathy (n = 11) 0.017 0.2 0.183
0.2 0.3 0.1
0.4 0.4 0
0.4 0.4 0
0.003 0.003 0
0.6 0.6 0
0.2 0.3 0.1
0.3 0.3 0
0.6 0.5 20.1
0.16 0.4 0.24
Mean (SD) 0.3 (0.2) 0.3 (0.2) 0.1 (0.1)
Macular hole stage 3 0.2 0.2 0
(n = 20) 0.3 0.3 0
Continued
Table 3 Continued
VA
preoperatively
VA
postoperatively Change in VA
0.16 0.2 0.04
0.1 0.4 0.3
0.3 0.3 0
0.4 0.5 0.1
0.15 0.4 0.25
0.2 0.2 0
0.3 0.3 0
0.3 0.3 0
0.3 0.3 0
0.2 0.4 0.2
0.02 0.02 0
0.1 0.3 0.2
0.4 0.7 0.3
0.2 0.2 0
0.3 0.3 0
0.2 0.3 0.1
0.5 0.7 0.2
0.6 0.6 0
Mean (SD) 0.3 (0.1) 0.3 (0.2) 0.1 (0.1)
Visual acuity of 0.017 (1/60) equals fingers counting at 1 m, visual acuity of 0.003 (1/
300) equals hand movement at 1 m. The mean (SD) values for each patient group are
given below. The Kruskal–Wallis one-way analysis of variance by ranks did not show
any statistically significant difference between the patient groups (p.0.05).
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visual acuity and lens status were the only variables which proved
to explain the variance of TTR (multiple correlation coefficient:
0.494; phakic status: t = 2.767; p = 0.0084; and change in visual
acuity t = 2.924: p = 0.0056).
DISCUSSION
This is the first report to the authors’ knowledge about a
biochemical marker related to change in visual acuity after
vitrectomy and for measuring TTR in vitreous samples by
immunonephelometry. In the present study, high concentra-
tions of TTR (mean: 19 mg/l) were found in vitreous fluid of
cadaver eyes. The observed values are comparable with those
observed in cerebrospinal fluid (mean: 17 mg/l). The median
serum TTR levels are 300 mg/l (IQR 250 to 350 mg/l). The total
protein levels in vitreous fluid are 538 mg/l and are comparable
with total protein levels in serum and in CSF (150 to 500 mg/l).
Total protein levels in serum are much higher (646103 to
836103 mg/l). The reference TTR/total protein ratios in the
vitreous (2.2%) greatly exceed the TTR/total protein levels in
serum (0.4% to 0.5%). The reference TTR values correlated with
total protein levels in the vitreous. The origin of vitreous
proteins includes the tissues surrounding the vitreous, the
hyalocytes of the vitreous or the surrounding vasculature. The
much higher TTR/total protein ratios found in the vitreous as
compared with serum values suggest that simple diffusion from
the serum cannot be the source of vitreous TTR. We conclude
that the physiological level of TTR found in the vitreous of
cadaver eyes is derived from surrounding tissues as RPE cells.
We found a significant correlation between postoperative
change in visual acuity and high TTR concentrations in the
vitreous preoperatively. Ramakrishnan et al found low TTR
levels in the vitreous of patients with diabetes.15 TTR levels in
the former study, however, were not measured by immunone-
phelometry but calculated semiquantitatively by densitometry
after electrophoresis. Our results show that TTR levels in the
vitreous are related not to diagnosis but to RPE function. TTR
expression is a marker of differentiation of RPE cells in vitro.8
We presume a higher metabolic state of RPE cells in patients
with high TTR expression, and thus a better regeneration after
a vitrectomy procedure.
The function of TTR in the vitreous remains to be elucidated.
RPE of the eye and choroid plexus of the brain are develop-
mental and functional homologues, sharing many of the
characteristics of transporting epithelia: the cells are joined by
tight apical membrane junctions, and they regulate the
transport of fluids and serum proteins into their respective
humours. The secretion of TTR by the choroid plexus of the
brain provides the mechanism for the regulation of T4
(thyroxin) levels in the brain. TTR in the CSF is involved in
the delivery of T4 to stem cells and progenitor cells within the
brain, which require T4 for regulation of the cell cycle.16 17 The
abundance of TTR mRNA in RPE is, except for the choroid
plexus in the brain, unmatched by any other tissue of the body.8
TTR protein is secreted predominantly in an apical direction by
RPE cells in vitro.18 The fact that the retinol metabolism is
altered in TTR-null mice suggests that TTR plays a major role
in the retinol metabolism in the interphotoreceptor matrix
(IPM).19 Interphotoreceptor retinoid-binding protein (IRBP), a
non-selective scavenger and stabiliser of retinoids released from
photoreceptors and pigment epithelial cells, is the most
abundant soluble protein component of the IPM. IRBP plays a
direct role in the release of all-trans retinol from the rods.20 All-
trans retinol generated in rod photoreceptors upon the bleaching
of rhodopsin is known to move from the rods to the RPE, where
it is enzymatically converted to 11-cis retinal in the retinoid
visual cycle. Experiments conducted on toad RPE-eyecups,
mammalian RPE cells and isolated RPE membranes indicate
that IRBP specifically promotes the release of 11-cis retinal from
the RPE apical surface, a step necessary for the movement of 11-
cis retinal to the rods.21 IRBP thereby directly supports the
regeneration of rhodopsin in the visual cycle.22 An emerging
concept is that the central role of retinoid-binding proteins in
the visual cycle is to achieve tight control of retinoid
concentration while protecting the retinal cells from the
toxicity of free retinoids. In analogy with the CSF where
thyroxin concentrations are titrated by binding to TTR, a
spatial gradient of free IRBP molecules and IRBP/retinoid
complexes might as well be regulated by TTR in the IPM.
We found higher TTR concentrations in phakic patients than
in pseudophakic patients. The vitreous proteome is found to be
different in pseudophakic patients.23 Lens cortical fibre debris,
for example, leaks into the vitreous during cataract extraction.
Cataract surgery might thus account for the easier passage of
TTR from the posterior chamber to the anterior chamber,
resulting in a higher outflow via the trabecular meshwork.
The total protein levels in the vitreous of patients with
diabetes were 4.3-fold higher than the reference total protein
levels. Electrophoresis of vitreous fluid proteins in diabetics
revealed a plasma-like protein pattern, suggesting that the
increased protein concentration is due to a major diffusion from
the pathological vessels. Increased vascular permeability and
pathological neovascularisation are major aspects of diabetic
retinopathy. Reduced integrity of adherens junctions and tight
junctions of human diabetic retina have been reported.24 25 TTR
values in the vitreous of patients with diabetes were fairly
similar to reference TTR values, as can be deduced from the
following example. A vitreous cavity with a 4 ml content filled
with blood corresponds to an influx of only 12 mg TTR from the
serum into the vitreous cavity (3 mg/l TTR 64 ml). The
amount of TTR that has originated from the serum into the
vitreous cavity cannot cause a significant rise in the TTR
concentration already present in the vitreous.
In conclusion, vitreous TTR concentrations strongly exceed
the values obtained in serum. Therefore, their concentrations in
vitreous fluid reflect local production by the RPE. The present
study suggests that TTR can be used as a biochemical marker
for assessing retinal function.
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Table 4 Reference values and values for total protein and transthyretin
(TTR) in vitreous fluid of the various patient groups
Retinal condition
Total protein (mg/l) TTR (mg/l) TTR/total protein (%)
Median (IQR) Median (IQR) Median (IQR)
Reference 538 (269 to 987) 18 (4 to 24) 2.2 (0.9 to 3.9)
RRD.1 week old 781* (460 to 1881) 19 (12 to 24) 1.6 (0.6 to 3.3)
RRD,1 week old 816* (427 to 1527) 14 (7 to 25) 1.8 (1.7 to 3.1)
Diabetes mellitus 2326* (1880 to 2818) 20 (10 to 24) 1.3 (1.2 to 1.4)
Macular hole 701 (241 to 1456) 13 (9 to 25) 1.5 (1.1 to 3.2)
The within- and between-run values for total protein and TTR are summarised.
*p,0.05 versus reference values; Mann–Whitney U test.
IQR, interquartile ratio; RRD, rhegmatogenous retinal detachment.
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medical therapy (by Norbert Pfeiffer, Mainz)
to the different laser techniques and the
numerous surgical options. Trabeculectomy
might still be the gold standard, but it
increasingly has its competitors: shunts may
be relatively safe and effective even as
primary surgery for primary glaucomas, as
Keith Barton (London) points out, while for
Robert Stegmann, ‘‘Schlemm’s canal surgery
will continue to play an increasing role in
the management of glaucoma as it is the
most physiologic way to approach it.’’
Glaucoma therapy will remain one of the
most challenging tasks for the ophthalmol-
ogist—and at the same time promises new
developments like those that have propelled
glaucoma diagnostics forward, for the ben-
efit of our patients, so impressively. The
annual Basel meeting and the book series of
which Glaucoma Therapy: State of the Art is
the latest (it is not available in bookstores
but is now on sale online at http://www.
glaucoma-meeting.ch) help to keep the
audience and the readers in touch with a
dynamic field of ophthalmology.
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Diabetic retinopathy for the
comprehensive ophthalmologist
By Jonathan Walker. Published by Deluma Medical, Fort
Wayne, 2009, pp 280, $39.99. ISBN-13 978-0-9821472-0-7
Diabetic Retinopathy for the Comprehensive
Ophthalmologist delivers exactly what it
promises: an appropriately balanced,
straightforward guide to the management
of diabetic retinopathy geared toward the
general ophthalmologist. This book is not
your traditional didactic reference. Informal
and light-hearted, even self-deprecating at
times, the author’s tone allows this book to
be read like a novel rather than a medical
textbook. He elegantly balances humour and
information, using anecdotes and mnemo-
nics to reinforce key points.
The author assumes his readership has
basic understanding of the ophthalmological
exam and ancillary tests, and foregoes a
primer on this subject. A thorough discussion
of the principles and use of lasers, however, is
included and is a must-read for retina fellows
or any ophthalmologist interested in adding
laser procedures to their armamentarium.
Residents as well as practising ophthalmolo-
gists will likely find useful the chapter on
pain control for patients undergoing panvet-
inal photocoagulation. An additional pearl is
a chapter on cataract surgery in patients with
diabetes, covering specific details regarding
preoperative evaluation, intraocular lens
selection, anaesthesia and management of
postoperative complications.
The chapters are concise and intuitively
organised with images from ancient and
historical ophthalmology texts adorning the
title pages. A reader can easily open this
book for 10 min and take away three or four
clinical pearls. Colour photographs under-
score key principles, particularly in the
chapter entitled ‘‘You Should Not Do
Magic You Do Not Understand:
Complications of Laser Treatment.’’ The
images of complications and ‘‘near-compli-
cations’’ serve admirably as reminders of the
potential dangers of ophthalmic lasers.
Large, straightforward figures are found
throughout the text, including useful tables
for the appropriate timing of follow-up and
figures detailing key information from the
landmark papers on diabetic retinopathy.
Also interspersed in the chapters are ‘‘boxes’’
containing practical advice that cannot be
found in many desk references. These
include tips on counselling patients prior to
procedures and preparing them for the
inevitable pitfalls they are likely to encoun-
ter due to their diabetic eye disease. By
adopting these techniques, ophthalmologists
will better garner the trust and confidence of
their patients and reduce time spent explain-
ing during future visits.
Diabetic Retinopathy for The
Comprehensive Ophthalmologist is available
for purchase at Amazon.com for $39.99. If
you cannot afford the purchase price, the
author has generously made the entire text-
book available as a free download at http://
www.drcobook.com
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CORRECTION
doi:10.1136/bjo.2009.158048corr1
Van Aken E, De Letter EA, Veckeneer M, et
al. Transthyretin levels in the vitreous
correlate with change in visual acuity after
vitrectomy (Br J Ophthalmol 2009;93:1539–
45). Line 8 of the Discussion should read
‘‘Total protein levels in vitreous fluid are
538 mg/l and are comparable with total
protein levels in CSF (150–500 mg/l); ie,
‘‘in serum and’’ should have been omitted.
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